Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week randomized double-blind placebo-controlled dose-ranging Phase 2 study of SAR425899 in type 2 diabetes mellitus
2016-001328-77Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bamadutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoint: Change in HbA1c. Started Nov 2016; status: completed.
02
Drugs
bamadutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-001328-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001328-77.